Seeking Alpha

RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the treatment ...
Seeking Alpha

RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis

NORTH CHICAGO, Ill., June 4, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced that RINVOQ ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older ...